Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.
Clarivate Plc (NYSE: CLVT) is a leading global provider of transformative intelligence, offering enriched data, insights, analytics, workflow solutions, and expert services across various sectors including Academia & Government, Intellectual Property, and Life Sciences & Healthcare. Formerly part of Thomson Reuters, Clarivate became an independent company in 2016 and went public on the New York Stock Exchange in 2019. The company is headquartered in London with operations in over 100 countries and a workforce of over 4,000 employees.
Clarivate serves a diverse clientele, ranging from academia, government, law, life sciences, and healthcare. Some of its most trusted brands include Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor®, and Techstreet™. These brands offer specialized services such as scientific and academic research, patent analytics, pharmaceutical and biotech intelligence, and IP management. Researchers and organizations globally rely on Clarivate's curated knowledge bases to accelerate innovation and bring new ideas to market more efficiently.
Recently, Clarivate has been recognized for its ongoing efforts and achievements. The company has made significant strides in the realm of cancer treatment research, particularly in the area of CAR T-cell therapies. According to a three-part report published by BioWorld™, Clarivate is exploring the rapid pipeline growth and clinical trials in CAR T therapy development in China. This report is part of the company’s commitment to providing valuable insights into groundbreaking treatments and their potential market impacts.
Additionally, Clarivate has launched key updates to its Cortellis CMC Intelligence™ solution, introducing a new post-approval variations module. This update assists pharmaceutical, biotech, and generics companies in streamlining regulatory tracking and optimizing lifecycle management for both small molecules and biologics.
The company also introduced Epidemiology Intelligence™, combining epidemiological data with U.S. claims-based population insights to help biopharma companies accurately gauge market size and target patient demographics. Another significant launch was the Trademark Watch Analyzer, an AI-enhanced trademark protection solution providing faster and more accurate answers to critical business questions by leveraging global trademark and case law data.
Financially, Clarivate reported a slight decrease in revenues for the first quarter of 2024, yet showed resilience and strategic focus on long-term growth. The company continues to invest in product development and operational initiatives to drive future organic revenue growth. Their financial stability is underscored by substantial cash flow and a clear strategy for debt management.
Clarivate’s strategic partnerships, such as the recent collaboration with HealthWise Data, further enhance its offerings by integrating Social Determinants of Health (SDoH) attributes into its Real-World Data repository, contributing to enhanced patient outcomes and healthcare equity.
For more information about Clarivate, its products, and services, visit www.clarivate.com.
Newfold Digital has successfully acquired MarkMonitor™, an enterprise-level domain management provider, from Clarivate Plc (NYSE:CLVT) as of November 1, 2022. The acquisition enhances Newfold's capabilities in establishing and protecting online presence for businesses. CEO Sharon Rowlands emphasized MarkMonitor’s expertise and commitment to security, aiming for ongoing improvements in customer service. This is part of Newfold's strategy to expand its product offerings and enhance customer experience across its global operations.
On November 1, 2022, Clarivate Plc (NYSE:CLVT) announced the successful divestiture of MarkMonitor™ to Newfold Digital for $302.5 million. This strategic move allows Clarivate to concentrate on its core intellectual property portfolio. The net cash proceeds will aid in reducing outstanding debt, enhancing the company's financial position. The deal was previously announced on September 12, 2022, and aligns with Clarivate's mission to accelerate innovation through focused investments.
Clarivate Plc (CLVT) released a report highlighting that innovation in sustainable energy is declining, particularly in solar and wind power, which are nearing technical maturity. Although these energies have seen significant research over the last three decades, the report suggests that activity is slowing down. Oceanic power is still developing, showing potential but currently lacking maturity.
China leads in renewable energy innovation, outpacing the U.S. in patent activity. The study provides insights into research gaps and trends, aligning with global sustainability goals.
Clarivate Plc (NYSE:CLVT) has released a report titled RNA Technology Companies to Watch, highlighting seven innovative companies in the RNA technology space. These firms are addressing undruggable disease targets, demonstrating potential benefits such as fewer side effects and enhanced efficacy. The report notes a significant increase in RNA-related scientific research and patent filings, with the U.S. and Mainland China leading advancements. Despite challenges in RNA stability and delivery, the sector remains promising.
Clarivate Plc (NYSE:CLVT) published a report analyzing formal regional research assessment systems across Australia, Canada, Germany, Hong Kong, New Zealand, and the UK. The report indicates improvements in comparative research performance but lacks a consensus on whether research assessment is essential. Key insights include Australia's unique methodology, Canada's focus on knowledge mobilization, and the UK's historical role in establishing research assessment models. The report also highlights potential biases in AI-driven assessments and their implications for the research ecosystem.
On Sept. 28, 2022, Clarivate Plc (NYSE: CLVT) announced it will report its third quarter 2022 financial results on November 8, 2022, before market opening. A conference call at 9:00 AM ET will follow for discussion on the results, accessible via the investor relations website. Additionally, the company is planning an Investor Day in the first quarter of 2023 post the fourth quarter results in February, where executives will update on strategy and fiscal 2023 guidance, alongside product demonstrations.
On September 22, 2022, Clarivate Plc (NYSE: CLVT) announced the launch of upgraded Web of Science™ Researcher Profiles, enhancing services for researchers by consolidating their academic publications, citation metrics, and peer review activities. This initiative, celebrated during Peer Review Week, aims to provide recognition for peer reviewers and support scholars in managing their contributions efficiently. Notably, researcher profile page views surged by nearly 320%, underlining the growing visibility of academic work. The upgraded platform offers various features to help researchers showcase their expertise and keep track of citation impacts.
On September 21, 2022, Clarivate Plc (NYSE: CLVT) announced its 2022 Citation Laureates, honoring 20 researchers whose work is recognized as 'of Nobel class'. The selection process utilized data from Web of Science, identifying highly cited publications out of more than 55 million indexed articles. Notable honorees include Masato Hasegawa, Virginia Man-Yee Lee, and Stephen R. Quake among others. Clarivate noted that 64 previous Citation Laureates have received Nobel Prizes, emphasizing the credibility of their research contributions.
Clarivate Plc (NYSE:CLVT) has announced the full migration of BioWorld Science to bioworld.com, completing the brand consolidation of its news portfolio. This transition enhances user experience with expanded news coverage and intuitive navigation. The new platform will provide readers daily access to comprehensive drug R&D news, including exclusive insights and in-depth articles, along with improved functionalities such as a daily newsletter. BioWorld aims to support critical decision-making in drug development by delivering timely and relevant information.
FAQ
What is the current stock price of Clarivate Plc (CLVT)?
What is the market cap of Clarivate Plc (CLVT)?
What does Clarivate do?
What are some of Clarivate’s trusted brands?
Where is Clarivate headquartered?
How did Clarivate become an independent company?
When did Clarivate go public?
What recent advancements has Clarivate made in the field of cancer treatment?
What is Cortellis CMC Intelligence™?
What is Epidemiology Intelligence™?
What is the purpose of the Trademark Watch Analyzer?
How does Clarivate enhance patient outcomes with HealthWise Data?
